Through enrichment analysis, we determined that FOXD2-AS1 may act as an oncogenic factor by regulating the EMT of tumor cells and by suppressing adaptive immunity through the inhibition of the function and proliferation of APCs. This evidence concerns the gene FOXD2 and neoplasm.